(CDAX, Technology, DAM GR)



Buy		Value Indicators:	EUR	Warburg Risk Score:	2.5	Description:	
Duy		DCF:	55.41	Balance Sheet Score:	5.0	Producer and Distributor of for special applications in the	
EUR <b>55.00</b>	(EUR 60.00)			Market Liquidity Score:	0.0	industry.	E
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2025e
		Market cap:	93.1	Freefloat	30.80 %	Beta:	1.5
Price	EUR 26.40	No. of shares (m):	3.5	Arrow Electronics	69.20 %	Price / Book:	0.6 x
Upside	108.3 %	EV:	76.8			Equity Ratio:	73 %
		Freefloat MC:	28.7				
		Ø Trad. Vol. (30d):	28.71 th				

### **Tough times**

Stated Figure	es Q4/2	024:					
Figures in EUR m	Q4/24	Q4/24e	Q4/23	yoy	2024	2023	yoy
Sales	53.9	51.5	71.4	-24.5%	226.2	283.2	-20.1%
EBIT	1.6	3.5	5.0	-66.9%	9.3	22.3	-58.2%
margin	3.0%	6.8%	6.9%		4.1%	7.9%	

#### Comment on Figures:


- Throughout the year, Data Modul faced significant economic pressure, and Q4 was no exception.
- The company reported figures that were slightly below the expectations (WRe) but in line with the adjusted forecast of the company.

Data Modul closed the 2024 financial year with a declining business performance in a challenging market environment. As the company had already adjusted its forecast for 2024 on October 18, the reported deviation did not come as a surprise. Business development is also expected to remain subdued in the medium term. As of the reporting date, the order backlog decreased by 12.9% year-on-year to EUR 141.3m (previous year: EUR 162.2m). The lingering effects of the COVID-19 crisis remain noticeable as government support measures have expired and high interest rates further hindered economic recovery. Additionally, the economic environment was shaped by the war in Ukraine, global trade conflicts, the newly intensified "America-First" strategy, tension between Taiwan and China, and increasing European regulations across almost all sectors. These factors posed significant challenges for Data Modul. The 2025 financial year is expected to be a difficult transition year, marked by a stronger market focus on new business opportunities while simultaneously implementing consistent cost-cutting measures. Given the current uncertainty in global economic environment, a recovery of Data Modul's key markets is unlikely in the short term. Assuming that the recession persists into the second half of the year, the management board expects a slightly negative development in the company's key financial figures. Under the assumption of a return to a solid EBIT margin of 7% by 2028 and 8% by 2031, the stock continues to be **rated Buy**. The price target is set at EUR 55 (previously EUR 60).

Changes in E	stimates:					
FY End: 31.12. in EUR m	2025e (old)	+/-	2026e (old)	+ / -	2027e (old)	+/-
Sales EBIT	241.7 14.5	-4.8 % -60.3 %	261.0 15.7	-7.5 %	n.a. n.a.	n.m. n.m.
EPS	2.57	-66.1 %	2.80	-41.8 %	n.a.	n.m.

#### Comment on Changes:

- An improvement in the situation is not expected even in the medium term.
- For this reason, estimates (WRe) are being further reduced.
- A significantly more cautious outlook now also seems realistic for 2025.




Rel. Performance vs CDAX:	
1 month:	2.8 %
6 months:	-19.7 %
Year to date:	-16.8 %
Trailing 12 months:	-50.6 %

Company events:	
08.05.25	Q1
08.05.25	AGM
08.08.25	Q2
07.11.25	Q3

FY End: 31.12. in EUR m	CAGR (24-27e)	2021	2022	2023	2024	2025e	2026e	2027e
Sales	4.9 %	194.8	276.1	283.2	226.2	230.0	241.5	260.8
Change Sales yoy		1.3 %	41.7 %	2.6 %	-20.1 %	1.7 %	5.0 %	8.0 %
Gross profit margin		21.8 %	23.1 %	21.0 %	18.8 %	17.5 %	18.0 %	20.0 %
EBITDA	3.7 %	18.6	33.0	28.4	21.2	13.8	17.7	23.6
Margin		9.5 %	11.9 %	10.0 %	9.4 %	6.0 %	7.3 %	9.1 %
EBIT	18.9 %	12.7	27.2	22.3	9.3	5.8	9.7	15.6
Margin		6.5 %	9.8 %	7.9 %	4.1 %	2.5 %	4.0 %	6.0 %
Net income	21.0 %	7.9	18.4	14.5	5.6	3.1	5.7	9.9
EPS	21.0 %	2.24	5.21	4.11	1.58	0.87	1.63	2.80
EPS adj.	21.0 %	2.24	5.21	4.11	1.58	0.87	1.63	2.80
DPS	0.0 %	0.12	0.12	0.12	0.12	0.12	0.12	0.12
Dividend Yield		0.2 %	0.2 %	0.2 %	0.4 %	0.5 %	0.5 %	0.5 %
FCFPS		-5.31	-1.76	4.22	5.13	-0.73	0.26	0.36
FCF / Market cap		-9.8 %	-3.1 %	7.7 %	15.9 %	-2.8 %	1.0 %	1.3 %
EV / Sales		1.0 x	0.7 x	0.7 x	0.4 x	0.3 x	0.3 x	0.3 x
EV / EBITDA		10.1 x	6.2 x	6.7 x	4.5 x	5.6 x	4.3 x	3.2 x
EV / EBIT		14.8 x	7.5 x	8.5 x	10.2 x	13.3 x	7.9 x	4.8 x
P/E		24.3 x	10.8 x	13.4 x	20.5 x	30.3 x	16.2 x	9.4 x
P / E adj.		24.3 x	10.8 x	13.4 x	20.5 x	30.3 x	16.2 x	9.4 x
FCF Potential Yield		4.5 %	7.0 %	8.1 %	17.0 %	8.4 %	11.9 %	17.5 %
Net Debt		-3.7	5.5	-5.2	-19.3	-16.3	-16.8	-17.6
ROCE (NOPAT)		9.3 %	15.0 %	11.2 %	4.8 %	3.0 %	4.8 %	7.4 %
Guidance:	Slightly negative	ve developm	ent of key fig	ures				

+49 40 309537-120






## **Company Background**

- Data Modul acts as a display integrator with a long experience in the market (50 years).
- With a global presence, Data Modul provides display and embedded solutions for OEMs.
- With its own products, Data Modul forms a value-adding interface between panel manufacturers and customers. Commercial products complete the offering.
- Markets dominated by megatrends such as industrial HMI, smart retail, medical and e-mobility are growing areas of increasing importance.

### **Competitive Quality**

- Europe's largest display distributor.
- Focus on niche markets that are too small or individual to be directly served by large display manufacturers, which leads to comparatively low competitive intensity.
- High customer loyalty through design-in of the customers' products and software competence.
- The global positioning of Data Modul (production/logistics in Europe, Asia, USA) enables competitively leading sourcing.





DCF model														
	Detailed	d forecas	t period				7	ransition	al period					Term. Value
Figures in EUR m	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	
Sales	221.7	232.8	251.4	269.0	287.8	305.1	320.3	336.4	353.2	370.8	389.4	408.8	421.1	
Sales change	-2.0 %	5.0 %	8.0 %	7.0 %	7.0 %	6.0 %	5.0 %	5.0 %	5.0 %	5.0 %	5.0 %	5.0 %	3.0 %	2.0 %
EBIT	5.8	9.7	15.6	18.8	20.1	21.4	25.6	26.9	28.3	29.7	31.1	36.8	37.9	
EBIT-margin	2.6 %	4.2 %	6.2 %	7.0 %	7.0 %	7.0 %	8.0 %	8.0 %	8.0 %	8.0 %	8.0 %	9.0 %	9.0 %	
Tax rate (EBT)	30.0 %	31.0 %	31.0 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	
NOPAT	4.0	6.7	10.8	12.9	13.8	14.6	17.6	18.4	19.4	20.3	21.3	25.2	26.0	
Depreciation	8.0	8.0	8.0	5.4	5.8	6.1	6.4	6.7	7.1	7.4	7.8	8.2	8.4	
in % of Sales	3.6 %	3.4 %	3.2 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	
Changes in provisions	0.0	0.0	0.0	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	
Change in Liquidity from														
- Working Capital	6.3	5.5	9.3	8.8	9.4	8.6	-24.2	-0.3	-0.7	-1.1	-1.5	-1.9	-4.7	
- Capex	8.0	8.0	8.0	5.4	5.8	6.1	6.4	6.7	7.1	7.4	7.8	8.2	8.4	
Capex in % of Sales	3.6 %	3.4 %	3.2 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	-2.3	1.2	1.5	4.4	4.5	6.1	41.8	18.8	20.1	21.5	22.9	27.2	30.8	24
PV of FCF	-2.3	1.1	1.3	3.3	3.1	3.8	23.5	9.6	9.3	8.9	8.6	9.3	9.5	87
share of PVs		0.00 %						50.46	6 %					49.54 %

Model parameter				Valuation (m)			
Derivation of WACC:		Derivation of Beta:		Present values 2037e	89		
				Terminal Value	87		
Debt ratio	5.00 %	Financial Strength	1.50	Financial liabilities	0		
Cost of debt (after tax)	1.7 %	Liquidity (share)	1.50	Pension liabilities	1		
Market return	8.25 %	Cyclicality	1.50	Hybrid capital	0		
Risk free rate	2.75 %	Transparency	1.50	Minority interest	0		
		Others	1.50	Market val. of investments	0		
				Liquidity	20	No. of shares (m)	3.5
WACC	10.54 %	Beta	1.50	Equity Value	195	Value per share (EUR)	55.41

	LIVILY Va	ue per Sha	are (EUR)	)													
		Terminal (	Frowth								Delta EBIT	-margin					
Beta \	WACC	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.69	11.5 %	47.45	47.91	48.39	48.90	49.44	50.00	50.60	1.69	11.5 %	38.76	42.14	45.52	48.90	52.28	55.67	59.05
1.60	11.0 %	50.27	50.81	51.37	51.97	52.60	53.27	53.98	1.60	11.0 %	41.27	44.83	48.40	51.97	55.54	59.11	62.67
1.55	10.8 %	51.80	52.38	52.99	53.64	54.32	55.05	55.82	1.55	10.8 %	42.63	46.30	49.97	53.64	57.31	60.98	64.65
1.50	10.5 %	53.41	54.04	54.70	55.41	56.15	56.95	57.79	1.50	10.5 %	44.08	47.86	51.63	55.41	59.18	62.96	66.74
1.45	10.3 %	55.12	55.80	56.52	57.29	58.10	58.97	59.89	1.45	10.3 %	45.62	49.51	53.40	57.29	61.18	65.07	68.96
1.40	10.0 %	56.92	57.66	58.45	59.29	60.18	61.12	62.14	1.40	10.0 %	47.25	51.26	55.27	59.29	63.30	67.31	71.32
1.31	9.5 %	60.87	61.75	62.69	63.69	64.76	65.90	67.13	1.31	9.5 %	50.86	55.13	59.41	63.69	67.97	72.24	76.52

<sup>•</sup> Revenue is expected to grow based on the continuous expansion in the use of display technology.

# Data Modul




Valuation							
	2021	2022	2023	2024	2025e	2026e	2027e
Price / Book	1.7 x	1.5 x	1.3 x	0.8 x	0.6 x	0.6 x	0.6 x
Book value per share ex intangibles	25.06	29.68	32.60	34.79	35.86	37.65	40.61
EV / Sales	1.0 x	0.7 x	0.7 x	0.4 x	0.3 x	0.3 x	0.3 x
EV / EBITDA	10.1 x	6.2 x	6.7 x	4.5 x	5.6 x	4.3 x	3.2 x
EV / EBIT	14.8 x	7.5 x	8.5 x	10.2 x	13.3 x	7.9 x	4.8 x
EV / EBIT adj.*	14.8 x	7.5 x	8.5 x	10.2 x	13.3 x	7.9 x	4.8 x
P/FCF	n.a.	n.a.	13.1 x	6.3 x	n.a.	103.4 x	74.3 x
P/E	24.3 x	10.8 x	13.4 x	20.5 x	30.3 x	16.2 x	9.4 x
P / E adj.*	24.3 x	10.8 x	13.4 x	20.5 x	30.3 x	16.2 x	9.4 x
Dividend Yield	0.2 %	0.2 %	0.2 %	0.4 %	0.5 %	0.5 %	0.5 %
FCF Potential Yield (on market EV)	4.5 %	7.0 %	8.1 %	17.0 %	8.4 %	11.9 %	17.5 %
*Adjustments made for: -							



Consolidated profit and loss							
In EUR m	2021	2022	2023	2024	2025e	2026e	2027
Sales	194.8	276.1	283.2	226.2	230.0	241.5	260.8
Change Sales yoy	1.3 %	41.7 %	2.6 %	-20.1 %	1.7 %	5.0 %	8.0 %
COGS	152.4	212.2	223.7	183.7	189.8	198.0	208.7
Gross profit	42.4	63.8	59.6	42.5	40.3	43.5	52.2
Gross margin	21.8 %	23.1 %	21.0 %	18.8 %	17.5 %	18.0 %	20.0 %
Research and development	5.7	6.7	7.2	6.1	6.9	7.2	7.8
Sales and marketing	25.0	30.1	30.2	29.2	27.6	26.6	28.7
Administration expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other operating expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other operating income	1.0	0.1	0.0	2.1	0.0	0.0	0.0
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	18.6	33.0	28.4	21.2	13.8	17.7	23.6
Margin	9.5 %	11.9 %	10.0 %	9.4 %	6.0 %	7.3 %	9.1 %
Depreciation of fixed assets	1.2	0.8	5.5	6.9	3.0	3.0	3.0
EBITA	17.4	32.2	23.0	14.3	10.8	14.7	20.6
Amortisation of intangible assets	4.7	5.0	0.7	5.0	5.0	5.0	5.0
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	12.7	27.2	22.3	9.3	5.8	9.7	15.6
Margin	6.5 %	9.8 %	7.9 %	4.1 %	2.5 %	4.0 %	6.0 %
EBIT adj.	12.7	27.2	22.3	9.3	5.8	9.7	15.6
Interest income	0.0	0.7	0.5	0.1	0.1	0.1	0.1
Interest expenses	1.4	0.9	1.9	1.4	1.4	1.4	1.4
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	11.3	26.9	20.9	8.0	4.4	8.3	14.3
Margin	5.8 %	9.7 %	7.4 %	3.5 %	1.9 %	3.4 %	5.5 %
Total taxes	3.4	8.5	6.4	2.4	1.3	2.6	4.4
Net income from continuing operations	7.9	18.4	14.5	5.6	3.1	5.7	9.9
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	7.9	18.4	14.5	5.6	3.1	5.7	9.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	7.9	18.4	14.5	5.6	3.1	5.7	9.9
Margin	4.1 %	6.7 %	5.1 %	2.5 %	1.3 %	2.4 %	3.8 %
Number of shares, average	3.5	3.5	3.5	3.5	3.5	3.5	3.5
EPS	2.24	5.21	4.11	1.58	0.87	1.63	2.80
EPS adj.	2.24	5.21	4.11	1.58	0.87	1.63	2.80
*Adjustments made for:							

Guidance: Slightly negative development of key figures


Financial Ratios							
	2021	2022	2023	2024	2025e	2026e	2027e
Total Operating Costs / Sales	15.2 %	13.3 %	13.2 %	14.7 %	15.0 %	14.0 %	14.0 %
Operating Leverage	5.5 x	2.7 x	-6.9 x	2.9 x	-22.9 x	13.6 x	7.7 x
EBITDA / Interest expenses	13.1 x	34.8 x	15.3 x	14.9 x	9.6 x	12.4 x	16.6 x
Tax rate (EBT)	30.1 %	31.6 %	30.7 %	30.1 %	30.0 %	31.0 %	31.0 %
Dividend Payout Ratio	5.4 %	2.3 %	2.9 %	7.6 %	13.7 %	7.4 %	4.3 %
Sales per Employee	416,184	589,857	578,031	461,649	460,000	483,000	521,640





Consolidated balance sheet							
In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Assets							
Goodwill and other intangible assets	25.6	27.1	29.7	28.4	27.4	26.4	25.4
thereof other intangible assets	23.1	24.7	27.0	26.0	25.0	24.0	23.0
thereof Goodwill	2.4	2.4	2.4	2.4	2.4	2.4	2.4
Property, plant and equipment	17.7	17.7	22.9	21.1	22.1	23.1	24.1
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	43.2	44.8	52.6	49.6	49.6	49.6	49.6
Inventories	86.7	109.8	100.2	95.8	97.5	102.3	110.5
Accounts receivable	29.2	37.6	41.1	29.5	30.2	31.8	34.3
Liquid assets	20.2	15.7	14.3	20.4	17.4	17.9	18.7
Other short-term assets	9.4	14.2	11.0	14.8	14.8	14.8	14.8
Current assets	145.6	177.2	166.6	160.6	159.9	166.8	178.3
Total Assets	188.8	222.0	219.2	210.1	209.5	216.4	227.9
Liabilities and shareholders' equity							
Subscribed capital	10.6	10.6	10.6	10.6	10.6	10.6	10.6
Capital reserve	24.1	24.1	24.1	24.1	24.1	24.1	24.1
Retained earnings	78.5	96.2	109.0	115.1	117.9	123.3	132.8
Other equity components	0.7	0.9	1.0	1.3	1.3	1.2	1.1
Shareholders' equity	113.9	131.8	144.6	151.1	153.9	159.2	168.6
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	113.9	131.8	144.6	151.1	153.9	159.2	168.6
Provisions	23.7	22.5	24.8	22.6	23.2	23.9	24.6
thereof provisions for pensions and similar obligations	1.5	1.2	1.1	1.1	1.1	1.1	1.1
Financial liabilities (total)	15.0	20.0	8.0	0.0	0.0	0.0	0.0
Short-term financial liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	21.0	19.7	21.0	21.0	17.0	17.9	19.3
Other liabilities	15.3	28.0	20.7	15.4	15.4	15.4	15.4
Liabilities	74.9	90.3	74.5	59.0	55.7	57.2	59.3
Total liabilities and shareholders' equity	188.8	222.0	219.2	210.1	209.5	216.4	227.9


Financial Ratios							
	2021	2022	2023	2024	2025e	2026e	2027e
Efficiency of Capital Employment							
Operating Assets Turnover	1.7 x	1.9 x	2.0 x	1.8 x	1.7 x	1.7 x	1.7 x
Capital Employed Turnover	1.8 x	2.0 x	2.0 x	1.7 x	1.7 x	1.7 x	1.7 x
ROA	18.3 %	41.0 %	27.6 %	11.2 %	6.2 %	11.6 %	19.9 %
Return on Capital							
ROCE (NOPAT)	9.3 %	15.0 %	11.2 %	4.8 %	3.0 %	4.8 %	7.4 %
ROE	7.2 %	15.0 %	10.5 %	3.8 %	2.0 %	3.7 %	6.0 %
Adj. ROE	7.2 %	15.0 %	10.5 %	3.8 %	2.0 %	3.7 %	6.0 %
Balance sheet quality							
Net Debt	-3.7	5.5	-5.2	-19.3	-16.3	-16.8	-17.6
Net Financial Debt	-5.2	4.3	-6.3	-20.4	-17.4	-17.9	-18.7
Net Gearing	-3.3 %	4.2 %	-3.6 %	-12.8 %	-10.6 %	-10.6 %	-10.5 %
Net Fin. Debt / EBITDA	n.a.	13.2 %	n.a.	n.a.	n.a.	n.a.	n.a.
Book Value / Share	32.3	37.4	41.0	42.9	43.6	45.1	47.8
Book value per share ex intangibles	25.1	29.7	32.6	34.8	35.9	37.7	40.6





Consolidated cash flow statement							
In EUR m	2021	2022	2023	2024	2025e	2026e	2027
Net income	7.9	18.4	14.5	5.6	3.1	5.7	9.9
Depreciation of fixed assets	1.2	8.0	5.5	6.9	3.0	3.0	3.0
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	4.7	5.0	0.7	5.0	5.0	5.0	5.0
Increase/decrease in long-term provisions	-0.1	-0.3	0.0	0.0	0.0	0.0	0.0
Other non-cash income and expenses	0.0	0.0	2.6	0.0	0.6	0.7	0.7
Cash Flow before NWC change	13.7	23.9	23.2	17.5	11.7	14.4	18.6
Increase / decrease in inventory	-34.7	-23.1	9.6	4.4	-1.7	-4.8	-8.2
Increase / decrease in accounts receivable	-5.0	-8.4	-3.5	11.5	-0.7	-1.6	-2.5
Increase / decrease in accounts payable	9.2	-1.2	1.2	0.0	-4.0	0.9	1.4
Increase / decrease in other working capital positions	1.2	6.0	-6.7	-11.7	0.0	0.0	0.0
Increase / decrease in working capital (total)	-29.4	-26.7	0.7	4.2	-6.3	-5.5	-9.3
Net cash provided by operating activities [1]	-15.7	-2.8	23.8	21.7	5.4	8.9	9.3
Investments in intangible assets	-3.0	-5.8	-3.0	-3.6	-4.0	-4.0	-4.0
Investments in property, plant and equipment	-4.0	-5.0	-6.0	0.0	-4.0	-4.0	-4.0
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Net cash provided by investing activities [2]	-3.0	-3.4	-9.0	-3.5	-8.0	-8.0	-8.0
Change in financial liabilities	15.0	5.0	-12.0	-8.0	0.0	0.0	0.0
Dividends paid	-0.4	-0.4	-0.4	-0.4	-0.4	-0.4	-0.4
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	-2.4	-2.9	-3.9	-3.4	0.0	0.0	0.0
Net cash provided by financing activities [3]	12.2	1.6	-16.3	-11.9	-0.4	-0.4	-0.4
Change in liquid funds [1]+[2]+[3]	-6.5	-4.6	-1.4	6.3	-3.0	0.5	0.8
Effects of exchange-rate changes on cash	0.1	0.0	0.0	-0.3	0.0	0.0	0.0
Cash and cash equivalent at end of period	20.2	15.7	14.3	20.4	17.4	17.9	18.7

Financial Ratios							
	2021	2022	2023	2024	2025e	2026e	2027e
Cash Flow							
FCF	-18.7	-6.2	14.9	18.1	-2.6	0.9	1.3
Free Cash Flow / Sales	-9.6 %	-2.2 %	5.3 %	8.0 %	-1.1 %	0.4 %	0.5 %
Free Cash Flow Potential	8.5	14.3	15.3	16.1	6.4	9.1	13.2
Free Cash Flow / Net Profit	-237.3 %	-33.7 %	102.8 %	324.3 %	-83.5 %	15.7 %	12.7 %
Interest Received / Avg. Cash	0.0 %	3.8 %	3.0 %	0.5 %	0.4 %	0.5 %	0.4 %
Interest Paid / Avg. Debt	18.9 %	5.4 %	13.3 %	35.6 %	n.a.	n.a.	n.a.
Management of Funds							
Investment ratio	3.6 %	3.9 %	3.2 %	1.6 %	3.5 %	3.3 %	3.1 %
Maint. Capex / Sales	3.4 %	3.7 %	2.4 %	1.2 %	2.6 %	2.5 %	2.3 %
Capex / Dep	119.5 %	184.9 %	145.9 %	30.1 %	100.0 %	100.0 %	100.0 %
Avg. Working Capital / Sales	40.9 %	40.3 %	43.8 %	49.7 %	46.8 %	47.0 %	46.3 %
Trade Debtors / Trade Creditors	139.4 %	190.7 %	195.9 %	140.8 %	177.6 %	177.7 %	177.7 %
Inventory Turnover	1.8 x	1.9 x	2.2 x	1.9 x	1.9 x	1.9 x	1.9 x
Receivables collection period (days)	55	50	53	48	48	48	48
Payables payment period (days)	50	34	34	42	33	33	34
Cash conversion cycle (Days)	212	205	182	196	203	204	208



Source, Walburg Nesearch

#### Data Modul



#### **LEGAL DISCLAIMER**

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

#### **COPYRIGHT NOTICE**

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

# DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <a href="http://www.mmwarburg.de/disclaimer/disclaimer/htm#Valuation">http://www.mmwarburg.de/disclaimer/disclaimer/htm#Valuation</a>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

#### SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



#### Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

# Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Data Modul	3, 5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005498901.htm



#### INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

<u>"_"</u>	Rating suspended:	The available information currently does not permit an evaluation of the company.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.

WARBURG RESEARCH GMBH -	ANALYSED RESEARCH	H UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	147	74
Hold	41	21
Sell	6	3
Rating suspended	6	3
Total	200	100

#### WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	40	78
Hold	7	14
Sell	1	2
Rating suspended	3	6
Total	51	100

#### PRICE AND RATING HISTORY DATA MODUL AS OF 25.03.2025



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode	+49 40 3282-2678		
Head of Equities	mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	Hannes Müller Software, IT	+49 40 309537-255 hmueller@warburg-research.com
Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Andreas Pläsier Banks, Financial Services	+49 40 309537-246 aplaesier@warburg-research.com
Stefan Augustin	+49 40 309537-168	Malte Schaumann	+49 40 309537-170
Cap. Goods, Engineering	saugustin@warburg-research.com	Technology	mschaumann@warburg-research.com
Jan Bauer Renewables	+49 40 309537-155 jbauer@warburg-research.com	Oliver Schwarz Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.com
Christian Cohrs Industrials & Transportation	+49 40 309537-175 ccohrs@warburg-research.com	Simon Stippig Real Estate, Telco	+49 40 309537-265 sstippig@warburg-research.com
<b>Dr. Christian Ehmann</b> BioTech, Life Science	+49 40 309537-167 cehmann@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Felix Ellmann Software, IT	+49 40 309537-120	Robert-Jan van der Horst	+49 40 309537-290 rvanderhorst@warburg-research.com
Jörg Philipp Frey	fellmann@warburg-research.com +49 40 309537-258	Technology  Andreas Wolf	+49 40 309537-140
Retail, Consumer Goods	jfrey@warburg-research.com	Software, IT	awolf@warburg-research.com
Marius Fuhrberg Financial Services	+49 40 309537-185 mfuhrberg@warburg-research.com		
Fabio Hölscher	+49 40 309537-240		
Automobiles, Car Suppliers	fhoelscher@warburg-research.com +49 40 309537-260		
Philipp Kaiser Real Estate, Construction	pkaiser@warburg-research.com		
Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com		
INSTITUTIONAL EQUIT	TY SALES		
Klaus Schilling	+49 69 5050-7400	Sascha Propp	+49 40 3282-2656
Head of Equity Sales, Germany Tim Beckmann	kschilling@mmwarburg.com +49 40 3282-2665	France	spropp@mmwarburg.com
United Kingdom	tbeckmann@mmwarburg.com		
Jens Buchmüller	+49 69 5050-7415		
Scandinavia, Austria  Matthias Fritsch	jbuchmueller@mmwarburg.com +49 40 3282-2696	Leyan likbahar	+49 40 3282-2695
United Kingdom, Ireland	mfritsch@mmwarburg.com	Roadshow/Marketing	lilkbahar@mmwarburg.com
Rudolf Alexander Michaelis	+49 40 3282-2649	Antonia Möller Roadshow/Marketing	+49 69 5050-7417
Germany Roman Alexander Niklas	rmichaelis@mmwarburg.com +49 69 5050-7412	Juliane Niemann	amoeller@mmwarburg.com +49 40 3282-2694
Switzerland, Poland, Italy	rniklas@mmwarburg.com	Roadshow/Marketing	jniemann@mmwarburg.com
SALES TRADING		DESIGNATED SPONSOF	RING
Oliver Merckel	+49 40 3282-2634	Marcel Magiera	+49 40 3282-2662
Head of Sales Trading  Bastian Quast	omerckel@mmwarburg.com +49 40 3282-2701	Designated Sponsoring Sebastian Schulz	mmagiera@mmwarburg.com +49 40 3282-2631
Sales Trading	bquast@mmwarburg.com	Designated Sponsoring	sschulz@mmwarburg.com
Christian Salomon	+49 40 3282-2685	Jörg Treptow	+49 40 3282-2658
Sales Trading	csalomon@mmwarburg.com	Designated Sponsoring	jtreptow@mmwarburg.com
MACRO RESEARCH Carsten Klude	+49 40 3282-2572	Dr. Christian Isonornoita	+49 40 3282-2439
Macro Research	cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	cjasperneite@mmwarburg.com
Our research can be fo	ound under:		
Warburg Research	research.mmwarburg.com/en/index.html	LSEG	www.lseg.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please contact			10 10 0000
Andrea Schaper Sales Assistance	+49 40 3282-2632 aschaper@mmwarburg.com	Kerstin Muthig Sales Assistance	+49 40 3282-2703 kmuthig@mmwarburg.com
	, 5 5		30 3.44